[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphatic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphatic-diseases":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100495434","a-prospective-natural-history-study-of-lymphatic-anomalies-100495434",false,"NCT05731141","A Prospective Natural History Study of Lymphatic Anomalies","* INCLUSION CRITERIA:\n\nAffected (Proband)\n\nIn order to be eligible to participate in this study, an individual must meet one of the following criteria as determined after review of medical history:\n\n* Current or history of lymphatic anomaly or symptoms suggestive of a lymphatic disorder Or\n* An ill-defined vascular anomaly that is suspected to have an abnormal lymphatic component Or\n* A pathogenic, likely pathogenic, or VUS in a genetic disorder with a known lymphatic component Or\n* Clinical diagnosis of a syndrome with a known lymphatic component\n\nUnaffected (First Degree Relatives: Parents and Siblings)\n\nGenetic variants underlying complex lymphatic anomalies can be passed down through parents or be new in a child (de novo). Inclusion of first-degree relatives will assist in genetic analysis to delineate whether the variant is inherited or de novo.\n\nTo be eligible to participate as a first degree relative in this study, an individual must be a first-degree family member of an affected participants\n\nEXCLUSION CRITERIA:\n\nAffected Proband\n\nAn individual who meets any of the following criteria will be excluded from participation in this study after review of medical history, concomitant medication and allergy review, anthropometrics, and performance status:\n\n-Any condition, in the opinion of the investigator, that would increase risk of participation or impair their ability to comply with protocol requirements.\n\nLymphatic anomalies that are definitively determined to be secondary by the principal investigator will be excluded from this study. For example, participants who develop a lymphedema after breast cancer surgery.\n\nUnaffected (First Degree Relatives)\n\n-Any condition, in the opinion of the investigator, that would increase risk of participation or impair their ability to comply with protocol requirements.",true,"ALL","1 Day","100 Years",{"count":20,"type":21},1200,"ESTIMATED","OBSERVATIONAL","Background:\n\nThe lymphatic system is a network of vessels that carry a clear fluid called lymph through the body. Problems in the lymphatic system can cause pain, fluid buildup, and issues with immunity. There is much researchers do not understand about lymphatic anomalies. In this natural history study, they will collect data from a lot of people over a long time.\n\nObjective:\n\nTo better understand why lymphatic anomalies develop. The goal is to improve future treatments.\n\nEligibility:\n\nPeople aged 0 days and older with a suspected or confirmed lymphatic anomaly. Their unaffected parents or siblings aged 7 years or older are also needed.\n\nDesign:\n\nParticipants may remain in the study indefinitely. Affected participants may be evaluated every 10 months to 2 years. Some participants will be seen over telemedicine. Others will be seen at the NIH Clinical Center for 2-5 days.\n\nAll participants will have a physical exam. They may provide specimens including blood, saliva, hair follicles, stool, skin, and other tissues. Samples may be used for genetic testing.\n\nParticipants may undergo other tests depending on their medical conditions. The NIH Clinical Center visit may include:\n\nHeart tests include placing stickers on the chest to measure electrical activity and using sound waves to capture pictures of the heart.\n\nA lung test measures the muscle strength in the chest. Participants will blow into a tube.\n\nPhotographs may be taken of participants faces and other features.\n\nImaging scans will take pictures of the inside of the body. One scan will measure bone density.\n\nOne type of scan tracks how lymph fluid moves through the body. Participants will be under anesthesia, and they will be injected with a dye.",[25,26],"Lymphatic Diseases","Lymphatic Abnormalities",[28,29,30,31,32,33,34,35,36,37],"Protein Losing Enteropathy","Lymphedema","Lymphangiectasia","Kaposiform Lymphangiomatosis","Gorham Stout Disease","Generalized Lymphatic Anomaly","Complex Lymphatic Anomaly","Chylous Effusion","Chylous Ascites","Central Conducting Lymphatic Anomaly","RECRUITING","2026-06-24",{"date":41,"type":42},"2026-06-25","ACTUAL",{"date":44,"type":42},"2023-03-20",{"date":46,"type":21},"2028-12-31",{"name":48,"class":49},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100167322","infusion-of-cell-populations-from-unlicensed-umbilical-cord-blood-units-100167322","NCT01451502","Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units","Inclusion Criteria:\n\nTo be eligible for an unlicensed umbilical cord blood (UCB) unit, the subject must meet each of the eligibility criteria listed below:\n\n* Subjects with any diagnosis for which there is an institutional review board (IRB) approved treatment protocol that requires UCB as a source of hematopoietic stem cells for lympho-hematopoietic reconstitution after myeloablative or non myeloablative conditioning.\n* Subject (or parent\u002Fguardian) must provide written informed consent for the use of unlicensed UCB units with co-enrollment onto a University of Minnesota IRB-approved clinical trial that details the disease specific treatment plan that prescribes the use of UCB as source of cells\n* Subject has an unlicensed UCB unit that meets required cell dose and HLA matching criteria (as defined in the primary treatment protocol) that is considered negative for tested blood-borne pathogens and also lack an 'equivalent', licensed UCB unit from a University of Minnesota approved Cord Blood Bank\n\nExclusion Criteria:\n\n* Exclusion criteria are specified in the treatment protocol according to indication.",{"count":57,"type":21},250,"INTERVENTIONAL",[60],"NA","For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic reconstitution or other form of cellular therapy, it is critical that the investigators have access to unlicensed UCB units.",[25,63],"Hematopoietic Malignancy",[65],"umbilical cord blood","2026-05-07",{"date":68,"type":42},"2026-05-08",{"date":70,"type":42},"2011-10-20",{"date":72,"type":21},"2027-02",{"name":74,"class":75},"Masonic Cancer Center, University of Minnesota","OTHER",1]